How does generic price-fixing harm patients?
Drugs named in Teva's indictment include pravastatin, warfarin, carbamazepine and tobramycin — old essentials that become very cheap under real competition — with uninsured patients paying increases directly and shortages arising when companies exit unprofitable markets.
Generics usually become very cheap when multiple manufacturers compete. When they allegedly coordinate instead, the price of old, essential medicines can rise sharply. The drugs named in Teva's indictment include widely used medicines such as pravastatin (cholesterol), warfarin (blood thinner), carbamazepine (seizures), clotrimazole (fungal infections) and tobramycin (eye infections). The DOJ also cited collusion on drugs for brain cancer, cystic fibrosis and hypertension, and on drugs for arthritis and seizures with Taro. Uninsured patients and those paying coinsurance feel increases directly, and government programmes and employers pay more. Price spikes on generics can also contribute to shortages when companies exit unprofitable markets. The alleged cartel therefore matters not only for its dollar value but for its effect on access to basic medicines.